ES / EN
- July 12, 2025 -
No Result
View All Result
OnCubaNews
  • World
  • Cuba
  • Cuba-USA
  • Opinion
    • Columns
    • Infographic
  • Culture
    • Billboard
  • Sports
  • Styles / Trends
  • Media
  • Special
  • Cuban Flavors
  • World
  • Cuba
  • Cuba-USA
  • Opinion
    • Columns
    • Infographic
  • Culture
    • Billboard
  • Sports
  • Styles / Trends
  • Media
  • Special
  • Cuban Flavors
OnCubaNews
ES / EN
Home Cuba

Cuba: COVID-19 vaccine project already tested on three researchers

After the test, the scientists have developed “a high immune response,” which will be confirmed after the second dose is applied in the next few days. In addition, the island will begin the clinical trials phase of Soberana 01 next Monday, with the administration of the drug to 40 people, and will extend the sample to 676 volunteers during the second phase, in September.

by
  • OnCuba Staff
    OnCuba Staff,
  • OnCuba editorial staff
August 21, 2020
in Cuba
0
Cuban vaccine candidate, Soberana 01. Photo: Gisela Rivero/Facebook.

Cuban vaccine candidate, Soberana 01. Photo: Gisela Rivero/Facebook.

Help us keep OnCuba alive

The Cuban COVID-19 vaccine project, named Soberana 01, was already tested on July 28 on doctors Vicente Vérez, director of the Finlay Institute of Vaccines (IFV), Yuri Valdés and Dagmar García, all of them principal investigators of the vaccine candidate.

After the test, the island’s three scientists have developed “a high immune response,” which will be confirmed after the second dose is applied in the next few days, as explained by Dr. Vérez quoted by the official Cubadebate website.

With Soberana 01, Cuba took an Olympic leap to enter the select and reduced group of countries that have specific vaccine candidates against the SARS-CoV-2 coronavirus. In fact, the Cuban project is the first in Latin America and already has the authorization of the Cuban regulatory authority on these issues: the Center for State Control of Quality of Medicines (CEDMED).

Cuba to start clinical trials of its own vaccine against new coronavirus

The phase of clinical trials with the vaccine, identified by the acronym FINLAY-FR-1, will begin next Monday, and will be supplied to a group of 20 persons aged between 19 and 59 years old. A week later, the trial will be applied to another twenty volunteers between 60 and 80 years old.

Related Posts

Sandra Sotolongo, co-director of the “inSurGENTES” project, during an activity in the vegetable garden. Photo: Courtesy.

Insurgents, an open-air revolution

July 10, 2025
Private business on Infanta and 23rd Streets, in Vedado, Havana. Photo: AMD.

MSMEs barely growing and their slowdown hinders competition and economic dynamism

July 9, 2025
Entrance to San Juan Park, located east of Santiago.

San Juan Hill: heritage in the attic?

July 6, 2025
Headquarters of the Matanzas People’s Court, where the trial was held. Photo: Matanzas People’s Court/Facebook.

Prosecutor’s Office requests up to 9 years in prison for synthetic drug trafficking in Matanzas

June 30, 2025

In the second phase, scheduled to begin on September 11, the sample will be expanded to 676 volunteers, including the 40 from the first phase.

During the presentation of the vaccine project, Dr. Vérez referred to the “low risks, few uncertainties and encouraging results” recorded in the preclinical phase, in which the drug was tested in mice and rabbits, and remains on trials on other animals.

Schedule of clinical trials for Soberana 01, Cuban COVID-19 vaccine candidate. Infographics: Juventud Técnica.

*Caption:

CUBAN VACCINE CANDIDATE vs COVID-19

Acronym for abbreviated title

SOBERANA 01

Purpose

Prevent Covid-19

Principal promoter

Finlay Institute of Vaccines

Type of participants:

Healthy volunteers

Age group to be studied:

19-80 years

Size of sample:

675 individuals

Some inclusion criteria:

>> Giving consent in writing

>> Being between 19-59 and 59-80 years old

>> Corporal mass rate between 18 and 29.9 kg/m2

Study’s key dates

First inclusion: 24/08/2020

Last inclusion: 30/10/2020

Termination: 11/01/2021

Available results: 1/02/2021

First publication: 15/02/2021

According to Dr. Dagmar García, on May 22 the RBD (Receptor Binding Domain) antigen was defined for the first time, because it is the most important protein fragment of the virus for its entry into the cell.

“This protein fragment is precisely the region of the virus that interacts with a receptor of the human cell, to penetrate the cell, which is why the vaccine strategy is to direct antibodies against that structure of the virus, with the aim of blocking this interaction of the viral protein with its receptor in the host,” stated García, quoted by Cubadebate.

The researchers wanted to use a vaccine platform in which they had previous experience, so they decided to combine this antigen with the meningococcal B outer membrane vesicle platform, which is the basis of the Cuban VA-MENGOC- BC® meningococcal meningitis vaccine.

According to Dr. García, “this element offers a lot of security to this vaccine candidate, because it is based on the platform of a vaccine that has been in use for more than 30 years. This immunogen also solved an epidemiological problem in the country and is used in the expanded immunization program, even in infants, with safety and high efficacy, which transmits peace of mind.”

https://twitter.com/FinlayInstituto/status/1296268854138634244?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1296268854138634244%7Ctwgr%5E&ref_url=https%3A%2F%2Foncubanews.com%2Fcuba%2Fcuba-proyecto-de-vacuna-contra-la-covid-19-ya-fue-probado-en-tres-investigadores%2F

The research director of the Finlay Institute affirmed that, if the vaccine demonstrates efficacy in clinical trials, the island’s biotechnology and pharmaceutical industry has the capacity to produce the millions of doses necessary to immunize the Cuban population, and even for export.

Soberana 01 is the result of the collaboration of the Cuban government with its scientific institutions in the search for solutions to the COVID-19 pandemic.

In addition to the Finlay Institute of Vaccines and the Molecular Immunology Center, the Faculty of Chemistry of the University of Havana, the molecular biology laboratory of the Civil Defense Research Center and the Center for Genetic Engineering and Biotechnology are participating in the project.

The institutions’ alliance also involves the National Toxicology Center as the main site for the candidate’s clinical trials, and the Pedro Kourí Institute of Tropical Medicine (IPK).

  • OnCuba Staff
    OnCuba Staff,
  • OnCuba editorial staff
Tags: coronavirus in CubaCOVID-19 vaccineCuban science
Previous Post

83 new COVID-19 contagions in Cuba

Next Post

Cuba reports one death and only 17 new COVID-19 cases

OnCuba Staff

OnCuba Staff

OnCuba Staff

OnCuba Staff

Next Post
New COVID-19 cases in Cuba: 12 Cubans and five foreigners. Photo: Ernesto Mastrascusa/EFE/Archive.

Cuba reports one death and only 17 new COVID-19 cases

Photo: Ismael Francisco/AP.

Cuba, between the crisis, the adjustment and the new foreign currency stores

Photo: Agencia Cubana de Noticias (ACN).

Molecular Biology Laboratory to be inaugurated in Matanzas

Leave a Reply Cancel reply

The conversation here is moderated according to OnCuba News discussion guidelines. Please read the Comment Policy before joining the discussion.

Your email address will not be published. Required fields are marked *

Most Read

  • Long jumper Lester Lescay during his participation in the European Team Championships

    Lester Lescay: “I left Cuba because I didn’t want to spend my youth there.”

    18 shares
    Share 7 Tweet 5
  • San Juan Hill: heritage in the attic?

    14 shares
    Share 6 Tweet 4
  • Los Palacios, land of Cuban rice harvested by Vietnamese

    13 shares
    Share 5 Tweet 3
  • Trump reinstates hard-line Cuba embargo as Havana condemns US measure as “criminal”

    31 shares
    Share 12 Tweet 8
  • Life on the razor’s edge: the case of Willliam and Viviana

    9 shares
    Share 4 Tweet 2

Most Commented

  • Photo: Kaloian.

    Private sector and tourism in Cuba. Why not?

    12 shares
    Share 5 Tweet 3
  • About us
  • Work with OnCuba
  • Terms of use
  • Privacy Policy
  • Moderation policy for comments
  • Contact us
  • Advertisement offers

OnCuba and the OnCuba logo are registered® trademarks of Fuego Enterprises, Inc., its subsidiaries or divisions.
OnCuba © by Fuego Enterprises, Inc. All Rights Reserved.

No Result
View All Result
  • World
  • Cuba
  • Cuba-USA
  • Opinion
    • Columns
    • Infographic
  • Culture
    • Billboard
  • Sports
  • Styles / Trends
  • Media
  • Special
  • Cuban Flavors

OnCuba and the OnCuba logo are registered® trademarks of Fuego Enterprises, Inc., its subsidiaries or divisions.
OnCuba © by Fuego Enterprises, Inc. All Rights Reserved.

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}